Anti-Nicotinic Acetylcholine Receptor beta antibody [EP2067Y] (ab76159)


  • Product nameAnti-Nicotinic Acetylcholine Receptor beta antibody [EP2067Y]
    See all Nicotinic Acetylcholine Receptor beta primary antibodies
  • Description
    Rabbit monoclonal [EP2067Y] to Nicotinic Acetylcholine Receptor beta
  • Tested applicationsSuitable for: WB, ICC, Flow Cytmore details
    Unsuitable for: IHC-P or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A synthetic peptide corresponding to residues in the extracellular region of human Nicotinic Acetylcholine Receptor beta

  • Positive control
    • Human brain lysate.
  • General notes

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.



Our Abpromise guarantee covers the use of ab76159 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/2000. Predicted molecular weight: 57 kDa.
ICC 1/100.
Flow Cyt 1/1000. ab172730-Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
  • Application notesIs unsuitable for IHC-P or IP.
  • Target

    • FunctionAfter binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
    • Involvement in diseaseDefects in CHRNB1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS) [MIM:601462]. SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes.
      Defects in CHRNB1 are a cause of congenital myasthenic syndrome with acetylcholine receptor deficiency (ACHRDCMS) [MIM:608931]. ACHRDCMS is a post-synaptic congenital myasthenic syndrome. Mutations underlying AChR deficiency cause a 'loss of function' and show recessive inheritance.
    • Sequence similaritiesBelongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Beta-1/CHRNB1 sub-subfamily.
    • Cellular localizationCell junction > synapse > postsynaptic cell membrane. Cell membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • Acetylcholine receptor protein beta chain precursor antibody
      • Acetylcholine receptor subunit beta antibody
      • ACHB_HUMAN antibody
      • AChR antibody
      • ACHRB antibody
      • Cholinergic receptor nicotinic beta polypeptide 1 (muscle) antibody
      • Chrnb 1 antibody
      • CHRNB antibody
      • chrnb1 antibody
      • CMS1D antibody
      • CMS2A antibody
      • Nicotinic acetylcholine receptor beta subunit precursor antibody
      • SCCMS antibody
      see all

    Anti-Nicotinic Acetylcholine Receptor beta antibody [EP2067Y] images

    • Overlay histogram showing SHSY-5Y cells stained with ab76159 (red line). The cells were fixed with 80% methanol (5 min) and incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab76159, 1/1000 dilution) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-rabbit IgG (H&L) (ab150077) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit IgG (monoclonal) (0.1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. This antibody gave a positive result in 4% paraformaldehyde (10 min) fixed SHSY-5Y cells used under the same conditions. Please note that Abcam do not have any data for use of this antibody on non-fixed cells. We welcome any customer feedback.
    • Anti-Nicotinic Acetylcholine Receptor beta antibody [EP2067Y] (ab76159) at 1/1000 dilution + human brain lysate at 10 µg

      goat anti-rabbit HRP at 1/2000 dilution

      Predicted band size : 57 kDa
      Observed band size : 57 kDa

    References for Anti-Nicotinic Acetylcholine Receptor beta antibody [EP2067Y] (ab76159)

    ab76159 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab76159.
    Please use the links above to contact us or submit feedback about this product.